

# **SUMMARY: POLY-MVA OUTCOME BASED INVESTIGATION**

1. These Clinical Oncology “Outcome Based” investigation over long periods are conducted on metastatic cancers of multiple origins.
2. The investigation was voluntary and not double-blinded or placebo controlled.
3. The major parameters included: CR – All Clinical disease in Remission  
PR – Greater than 50% reduction in tumor mass and/or markers  
SD – Less than 50% reduction in tumor mass/markers
4. 56% at 30 Month and 38% at 60 Month overall response rate (ORR) combining CR +PR +SD.
5. The ORR in patients on Poly-MVA *only* was 40%.
6. The ORR in patients on chemotherapy + Poly-MVA was 60%.
7. These results showed improvement over historical controls in each evaluation.

## **CONCLUSIONS OF POLY-MVA INVESTIGATION**

Poly-MVA is a safe both orally/IV and is extremely effective supplement for support and palliative assistance in stage IV cancer patients either with or without concomitant chemotherapy.

The safety profile is excellent and there were no treatment related deaths or any significant adverse reactions or negative interactions with chemotherapy or hormonal treatments.

The best responding tumors were: 1) Prostate, 2) Breast, 3) Lung. 4) Head/Neck, 5) CRC, and 6) Hematological  
Results show an improved QOL and Overall Response Rate over historical controls.

**An IV loading dose of Poly-MVA confers a 20% improved ORR in this investigation.**

### **Homeopathic Oncology Philosophy**

In Stage IV cancers of any origin; Improvement in *Quality of Life* issues is directly proportional to improvement to overall response rate.

Even stable disease can be tolerated and metamorphosed into a chronic livable condition. This is true provided that this improvement is not gained at the expense of toxic chemotherapy or radiation therapy leaving the patient with many of the following adverse side effects:

- Chemo Brain Syndrome
- Severe Pancytopenias
- Painful Neuropathies
- Pulmonary Fibrosis
- Cardiomyopathies
- Devastating Fatigue, Anorexia and Wasting Syndromes
- Renal and Hepatic Failure
- Osteoarthritis, Myalgias
- Death

**These studies and the various case reports continue to confirm that the “cure or kill” approach to cancer treatment is not the only solution and more research is needed.**